Skip to main content
Top
Published in: Annals of Surgical Oncology 6/2020

01-06-2020 | Melanoma | Melanoma

Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease

Authors: Abhineet Uppal, MD, Stacey Stern, MS, John F. Thompson, MD, Leland Foshag, MD, Nicola Mizzollo, MD, Omgo E. Nieweg, MD, PhD, Harald J. Hoekstra, MD, Daniel F. Roses, MD, Vernon K. Sondak, MD, Mohammed Kashani-Sabet, MD, Brendon J. Coventry, MD, PhD, Alistair J. Cochran, MD, Manabu Fujita, MD, Myung Sim-Shin, PhD, David Elashoff, PhD, Robert M. Elashoff, PhD, Mark B. Faries, MD

Published in: Annals of Surgical Oncology | Issue 6/2020

Login to get access

Abstract

Background

Recommended treatment for patients with sentinel lymph node (SLN)-positive melanoma has recently changed. Randomized trials demonstrated equivalent survival with close observation versus completion lymph node dissection (CLND), but increased regional node recurrence. We evaluated factors related to in-basin nodal recurrence after lymphadenectomy (LND) for SLN-positive or macroscopic nodal metastases.

Methods

An institutional database and the first Multicenter Selective Lymphadenectomy Trial (MSLT-I) were analyzed independently. Exclusions were multiple primaries, multi-basin involvement, or in-transit metastases. Patient demographics, primary tumor thickness and ulceration, lymph nodes retrieved, and use of adjuvant radiotherapy were analyzed. Multivariate analyses were performed to determine factors predicting in-basin nodal recurrence (significance p ≤ 0.05).

Results

The retrospective cohort (577 patients) showed an in-basin failure rate of 6.6% after CLND for a positive SLN and 13.1% after LND for palpable disease (p = 0.001). This recurrence risk persisted after adjustment for patient, tumor, and LND factors [hazard ratio (HR) 2.32; p = 0.004]. In the MSLT-I cohort (326 patients), the failure rate after CLND following SLNB was 6.2%, but 10.1% after LND for palpable recurrence in observation patients. After adjustment for other factors, macroscopic disease was associated with an increased risk of recurrence after LND (HR 2.24; p = 0.05).

Conclusion

After LND for melanoma, in-basin recurrence is infrequent, but a clinically significant fraction will fail. Failure is less likely if dissection is performed for clinically occult disease. Further research is warranted to evaluate the long-term regional control and quality of life associated with nodal basin observation, which has now become standard practice.
Literature
1.
go back to reference Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRef Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRef
2.
go back to reference Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRef Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRef
3.
go back to reference Pidhorecky I, Lee RJ, Proulx G, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol. 2001;8:109–15.CrossRef Pidhorecky I, Lee RJ, Proulx G, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol. 2001;8:109–15.CrossRef
4.
go back to reference Calabro A, Singletary E, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–5.CrossRef Calabro A, Singletary E, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051–5.CrossRef
5.
go back to reference Nathansohn N, Schachter J, Gutman H. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg. 2005;140(12):1172–7.CrossRef Nathansohn N, Schachter J, Gutman H. Patterns of recurrence in patients with melanoma after radical lymph node dissection. Arch Surg. 2005;140(12):1172–7.CrossRef
6.
go back to reference White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235:879–87.CrossRef White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235:879–87.CrossRef
7.
go back to reference Fisher SR. Cutaneous malignant melanoma of the head and neck. Laryngoscope. 1989;99:822–36.CrossRef Fisher SR. Cutaneous malignant melanoma of the head and neck. Laryngoscope. 1989;99:822–36.CrossRef
8.
go back to reference Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.CrossRef Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.CrossRef
9.
go back to reference Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. J Clin Oncol. 2018;36:3441–9.CrossRef Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. J Clin Oncol. 2018;36:3441–9.CrossRef
Metadata
Title
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease
Authors
Abhineet Uppal, MD
Stacey Stern, MS
John F. Thompson, MD
Leland Foshag, MD
Nicola Mizzollo, MD
Omgo E. Nieweg, MD, PhD
Harald J. Hoekstra, MD
Daniel F. Roses, MD
Vernon K. Sondak, MD
Mohammed Kashani-Sabet, MD
Brendon J. Coventry, MD, PhD
Alistair J. Cochran, MD
Manabu Fujita, MD
Myung Sim-Shin, PhD
David Elashoff, PhD
Robert M. Elashoff, PhD
Mark B. Faries, MD
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-08086-0

Other articles of this Issue 6/2020

Annals of Surgical Oncology 6/2020 Go to the issue